Intellia Therapeutics Inc (NTLA)
24.87
+1.87
(+8.13%)
USD |
NASDAQ |
May 09, 16:00
24.56
-0.31
(-1.25%)
Pre-Market: 08:44
Intellia Therapeutics Research and Development Expense (Quarterly): 108.98M for Dec. 31, 2023
Research and Development Expense (Quarterly) Chart
Historical Research and Development Expense (Quarterly) Data
| Date | Value |
|---|---|
| December 31, 2023 | 108.98M |
| September 30, 2023 | 113.70M |
| June 30, 2023 | 115.28M |
| March 31, 2023 | 97.12M |
| December 31, 2022 | 100.03M |
| September 30, 2022 | 96.65M |
| June 30, 2022 | 90.20M |
| March 31, 2022 | 133.10M |
| December 31, 2021 | 71.16M |
| September 30, 2021 | 60.49M |
| June 30, 2021 | 58.88M |
| March 31, 2021 | 39.28M |
| December 31, 2020 | 38.23M |
| September 30, 2020 | 39.76M |
| June 30, 2020 | 37.77M |
| March 31, 2020 | 34.65M |
| December 31, 2019 | 31.73M |
| September 30, 2019 | 27.51M |
| Date | Value |
|---|---|
| June 30, 2019 | 25.46M |
| March 31, 2019 | 23.71M |
| December 31, 2018 | 19.92M |
| September 30, 2018 | 23.24M |
| June 30, 2018 | 23.47M |
| March 31, 2018 | 22.49M |
| December 31, 2017 | 21.17M |
| September 30, 2017 | 17.48M |
| June 30, 2017 | 15.56M |
| March 31, 2017 | 13.43M |
| December 31, 2016 | 11.33M |
| September 30, 2016 | 7.861M |
| June 30, 2016 | 7.423M |
| March 31, 2016 | 5.225M |
| December 31, 2015 | 4.375M |
| September 30, 2015 | 3.458M |
| June 30, 2015 | 1.966M |
| March 31, 2015 | 1.371M |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (Quarterly) Range, Past 5 Years
25.46M
Minimum
Jun 2019
133.10M
Maximum
Mar 2022
69.47M
Average
60.49M
Median
Sep 2021
Research and Development Expense (Quarterly) Benchmarks
| Moderna Inc | 1.063B |
| Regeneron Pharmaceuticals Inc | 1.248B |
| NeuroMetrix Inc | 0.7324M |
| Repligen Corp | 11.24M |
| Pacific Biosciences of California Inc | 44.54M |